RICHARD ORLOWSKI, MD

Plain English
This study compared two treatment options for women with advanced or recurrent endometrial cancer: a combination of lenvatinib and pembrolizumab versus traditional chemotherapy using paclitaxel and carboplatin. After one year of additional follow-up, the results showed that overall survival was similar with both treatments, with patients taking lenvatinib and pembrolizumab living for about 30.9 months compared to 29.4 months for those on chemotherapy. However, for patients with a specific type of cancer that has high mismatch repair deficiency, the lenvatinib and pembrolizumab combination allowed them to live longer without the disease worsening, lasting an average of 31.8 months compared to just 9 months with chemotherapy. Who this helps: This research benefits women with advanced endometrial cancer, especially those with mismatch repair-deficient tumors.

Plain English
This study looked at how effective a drug called pembrolizumab is when used with standard chemotherapy for patients with a specific type of endometrial cancer linked to poor outcomes (known as mismatch repair-deficient or dMMR tumors). The results showed that after two years, 92.4% of patients treated with pembrolizumab were free from cancer returning, compared to 80.2% of those who received a placebo. This matters because it suggests that pembrolizumab can significantly improve the chances of staying cancer-free for patients with these high-risk tumors. Who this helps: This benefits patients with newly diagnosed, high-risk endometrial cancer.

Plain English
This study compared a combination treatment of lenvatinib and pembrolizumab to traditional chemotherapy for patients with advanced endometrial cancer. While patients receiving the new treatment had a median survival of 37.7 months compared to 32.1 months for those on chemotherapy, the results did not meet the strict criteria to declare it a significant improvement. Additionally, 79% of patients on the new treatment experienced severe side effects, compared to 67% on chemotherapy. Who this helps: This research benefits patients with advanced endometrial cancer by providing insights into potential treatment options.

Plain English
This study looked at the results of stem cell transplants in patients with blood cancers who had recently received treatment with pembrolizumab, an immunotherapy drug. Among 70 patients analyzed, 44% were in remission at the time of their transplant, with good long-term outcomes—76.5% were alive after 40 months, and only 27% experienced cancer relapse during that time. The findings show that stem cell transplants can be a safe and effective option for these patients after they have undergone pembrolizumab therapy. Who this helps: This helps patients with hematologic malignancies looking for treatment options after immunotherapy.

Plain English
This study looked at how well a combination of two drugs, lenvatinib and pembrolizumab, works for patients with advanced endometrial cancer who had already received treatment. They found that the drugs were effective regardless of specific genetic markers or mutations, but none of the genetic tests they examined could predict how well patients would respond to the treatment. This finding is important because it shows that the drugs are beneficial for a broad range of patients with this cancer, even if their tumors have different genetic characteristics. Who this helps: This research benefits patients with advanced endometrial cancer.

Plain English
This study looked at the cost effectiveness of a new treatment, pembrolizumab plus lenvatinib, for women in Sweden with advanced endometrial cancer who have already had other treatments. The findings showed that this combination treatment can provide about 1.49 more quality-adjusted life years (QALYs) and 1.76 additional life years compared to chemotherapy, with costs of around 795,000 to 820,000 Swedish kronor per QALY gained. This matters because it shows that pembrolizumab plus lenvatinib offers a better value for money in improving patients' lives compared to existing chemotherapy options. Who this helps: This helps women with advanced endometrial cancer who have already received previous treatments.

Plain English
This study looked at whether adding a drug called pembrolizumab to chemotherapy helps patients with newly diagnosed, high-risk endometrial cancer that was completely removed by surgery. Researchers found that after following 1,095 patients, both groups (those receiving pembrolizumab and those receiving a placebo) had similar rates of disease-free survival after two years, at about 75% and 76% respectively. However, the drug seemed to benefit a specific group of patients with a certain type of tumor (dMMR), showing a better likelihood of staying disease-free. Who this helps: This research helps doctors better understand treatment options for patients with high-risk endometrial cancer.

Plain English
This paper studied the use of pembrolizumab, a type of immunotherapy, for treating breast and gynecologic cancers like triple-negative breast cancer, cervical cancer, and endometrial cancer. The research found that pembrolizumab is less damaging to patients' quality of life while being cost-effective compared to other treatments. Ongoing studies aim to explore its effectiveness in early-stage cancers, with the hope of curing more patients. Who this helps: This benefits patients with breast and gynecologic cancers and their healthcare providers.

Plain English
This study looked at treatment and outcomes for patients with advanced endometrial cancer that has specific genetic markers (MSI-high or dMMR) in the U.S. Among 124 patients who had already undergone an ineffective treatment, those who received immunotherapy (primarily pembrolizumab) had a median overall survival of 30 months, compared to just 7 months for those who got chemotherapy. This highlights that immunotherapy may offer significant benefits for these patients, changing the standard care approach for advanced endometrial cancer. Who this helps: Patients with advanced endometrial cancer that is MSI-high or dMMR who are not candidates for surgery.

Plain English
This study looked at the combination of two drugs, lenvatinib and pembrolizumab, in treating patients with advanced endometrial carcinoma (a type of uterine cancer) who had already received prior treatment. The researchers monitored 108 patients and found that nearly 40% (39.8%) responded well to the treatment, with responses lasting an average of about 22.9 months. Additionally, patients lived for an average of about 17.7 months after starting the treatment, although most experienced side effects like high blood pressure and fatigue. Who this helps: This benefits patients with advanced endometrial carcinoma looking for effective treatment options after other therapies have failed.

Plain English
This study examined the effects of a combination treatment, lenvatinib and pembrolizumab, on patients with advanced endometrial cancer who had already received other treatments. The results showed that this combination improved overall survival by 30% and progression-free survival by 40% compared to standard chemotherapy. Additionally, about 33.8% of all patients responded positively to the treatment, which is significantly higher than the 14.7% response rate observed with chemotherapy. Who this helps: This benefits patients with advanced endometrial cancer looking for more effective treatment options.

Plain English
This study looked at multiple myeloma patients to see how certain mutations (RAS/BRAF) affect their disease. Researchers found that about 32% of patients had these mutations and that those patients had worse blood counts, higher calcium levels, and were in more advanced disease stages compared to those without mutations. RAS/BRAF mutations were linked to much shorter survival times—69 months for those with mutations versus 221 months for those without, making it crucial to test for these mutations and consider new treatment options. Who this helps: This helps patients with myeloma and their doctors in tailoring treatment strategies.

Plain English
Researchers tested a new treatment using modified immune cells called CAR T cells in patients with advanced melanoma and triple-negative breast cancer. They found that out of the eight patients studied, six had mild side effects, and four showed stable disease, meaning their tumors did not grow during the treatment. This study is important because it shows that this new therapy is safe and may be a potential option for patients with limited treatment choices. Who this helps: This helps patients with metastatic melanoma and triple-negative breast cancer.

Plain English
This study looked at how well the combination of lenvatinib and pembrolizumab worked for Japanese patients with advanced endometrial cancer who had not responded to other treatments. The results showed that this combination therapy improved the length of time patients lived without their cancer getting worse, with a hazard ratio of 0.81 for all patients. It showed promising efficacy and that side effects were generally manageable; 36.5% of patients stopped at least one of the treatments due to side effects, compared to 7.8% in the other treatment group. Who this helps: This helps patients with advanced endometrial cancer looking for more effective treatment options.

Plain English
This study examined patients with multiple myeloma, a type of blood cancer, to find a better way to detect and monitor rare cancer cells in their blood, which are often missed in standard tests. Researchers used a new method that combines imaging and DNA sequencing on samples from five patients and found that rare cancer cells in the blood show the same genetic changes as those in the bone marrow, which helps in understanding how the disease spreads and recurs. This approach could lead to more accurate monitoring of the disease without the need for painful bone marrow biopsies. Who this helps: This benefits patients with multiple myeloma by providing a less invasive method for monitoring their disease.

Plain English
This study looked at two different testing methods for hepatitis C virus (HCV) in patients with blood cancers and those who received blood stem cell transplants. Out of 214 patients tested, only 1.4% had antibodies indicating past infection, while 0.9% had the active virus. The two tests were almost equally effective, agreeing 99.5% of the time, which means both are reliable for screening patients in this group. Who this helps: This benefits cancer patients and healthcare providers involved in their care.

Plain English
This study looked at the symptoms and quality of life of patients with relapsed or refractory multiple myeloma (RRMM) to better understand their experiences. Researchers found that 93% of patients were categorized as symptomatic, reporting severe fatigue, a poor appetite, and a significant decline in their overall quality of life compared to healthier individuals. For those undergoing therapy, factors like age, gender, existing health issues, and the length of their illness increased symptom burden and decreased quality of life. Who this helps: This information is valuable for patients, doctors, and caregivers working with individuals affected by multiple myeloma.

Plain English
This study looked at whether training emergency medical services (EMS) workers to focus more on resuscitation at the scene of cardiac arrests would lead to better survival rates for patients. Researchers found that after the training, the rate of stopping resuscitation efforts on the scene increased from 39.6% to 51.1%, and there was a trend showing improved survival rates to hospital discharge, especially for patients with good brain function. This matters because it suggests that better training for EMS can potentially save more lives and improve outcomes for people who experience cardiac arrests outside of the hospital. Who this helps: This helps patients who suffer from out-of-hospital cardiac arrests and their families.

Plain English
This study looked at how well the drug combination of lenvatinib and pembrolizumab works for patients with advanced endometrial cancer and what side effects they might experience. It found that over half (51%) of patients developed hypothyroidism, while significant cases of fatigue, hypertension, and nausea were reported in at least 5% of patients. Understanding and managing these side effects is crucial to help doctors provide better treatment for these patients. Who this helps: This helps patients with advanced endometrial cancer and their healthcare providers.

Plain English
This study looked at the effects of two drugs, lenvatinib and pembrolizumab, on patients with advanced endometrial cancer who had already undergone prior treatments. Researchers found that 38% of the 108 patients showed a positive response to the treatment after 24 weeks, with even higher rates (63.6%) in patients with specific tumor characteristics. This combination therapy not only shrank tumors effectively but also had a manageable safety profile, which is important for improving treatment options for these patients. Who this helps: This benefits patients with advanced endometrial cancer, especially those who have not seen success with previous treatments.

Plain English
This study examined the risk of multiple myeloma, a type of blood cancer, in African American (AA) patients compared to European American (EA) patients. Researchers found that AA patients had a significantly lower risk of progressing from a condition called monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma, with a 2-year risk of 5% for AA patients versus 15% for EA patients. This matters because it challenges previous assumptions about disease risk and highlights the need for tailored medical approaches based on patient backgrounds. Who this helps: This research benefits patients and doctors by providing better insights into disease risks based on race.

Plain English
Researchers studied the effectiveness of a drug called carfilzomib combined with other treatments for patients with multiple myeloma (MM) and Waldenström's macroglobulinemia (WM). They found that 98% of MM patients responded to treatment, and 77% went on to receive a stem cell transplant, while all WM patients reported significant improvements. This matters because carfilzomib-based treatments are safe and effective options for starting treatment for these diseases. Who this helps: This benefits patients newly diagnosed with multiple myeloma and Waldenström's macroglobulinemia.

Plain English
This study looked at a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find out more about genetic changes that could affect treatment. Researchers found that 27% of the 105 cases analyzed had specific gene alterations linked to a stronger immune response, which may help the body fight the cancer. Patients with these alterations had worse outcomes with standard treatments but responded better to a type of immunotherapy that blocks a protein called PD-1. Who this helps: This helps patients with DLBCL by identifying those who may benefit from specialized immunotherapy treatments.

Plain English
This study looked at a drug called pembrolizumab for treating patients with relapsed or refractory primary mediastinal large B-cell lymphoma, a type of cancer that often doesn’t respond to other treatments. The results showed that about 48% of patients in one group and 45% in another group saw their cancer improve, with some patients remaining cancer-free for over a year after stopping the treatment. This is important as it offers hope for better outcomes in a group of patients who currently have few effective options. Who this helps: This helps patients with relapsed or refractory primary mediastinal large B-cell lymphoma.

Plain English
This study looked at how specific immune reactions to certain antigens might influence the development of conditions like monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Researchers found that antibodies from patients with Gaucher disease and certain other gammopathies reacted strongly to fats called lysolipids, which suggests that these interactions can lead to more aggressive tumor growth in some patients. Understanding this relationship is important because it opens the door to new treatments that could prevent multiple myeloma from developing in at-risk patients. Who this helps: This research helps patients at risk for multiple myeloma, providing insights that could lead to better therapies.

Plain English
This study tested a new treatment approach for patients with untreated mantle cell lymphoma, using the drug bortezomib along with other established medications. Out of 95 patients, all responded to the treatment, and 82% experienced complete remission. Even though there were significant side effects, the treatment did not lead to more severe infections than previous treatments. Who this helps: This research benefits patients diagnosed with mantle cell lymphoma by exploring more effective treatment options.

Plain English
This study looked at how a molecule called miR-155 contributes to lung cancer's resistance to chemotherapy. Researchers found that when they blocked miR-155, it helped make cancer cells more sensitive to treatment, which could improve outcomes for patients. They also discovered that high levels of miR-155 combined with low levels of another molecule were associated with shorter survival in lung cancer patients. Who this helps: This helps lung cancer patients who are struggling with chemotherapy resistance.

Plain English
This research studied the drug ricolinostat, which specifically targets a protein involved in cancer cell survival, when combined with two other drugs, bortezomib and dexamethasone, for treating patients with relapsed or refractory multiple myeloma (a type of blood cancer). The study found that when ricolinostat was taken daily at a dose of 160 mg, about 37% of patients showed a positive response to treatment, and the combination therapy was generally safe and better tolerated than previous treatments that did not specifically target HDAC6. This matters because it offers a new potential strategy for addressing challenging cases of multiple myeloma with fewer side effects. Who this helps: This helps patients with relapsed or refractory multiple myeloma.

Plain English
Researchers studied the impact of a gene called ILF2 in multiple myeloma, a type of blood cancer, particularly in patients with a certain genetic change known as 1q21 amplification, which is present in 30% of new cases and 70% of relapsed cases. They found that higher levels of ILF2 help cancer cells survive DNA damage and resist treatments aimed at killing them, indicating that ILF2 plays a crucial role in how these cells adapt to stress. Understanding how ILF2 affects these processes could lead to better treatment strategies for patients with aggressive forms of multiple myeloma. Who this helps: This helps patients with high-risk multiple myeloma.

Plain English
This study looked at how often to give a medication called zoledronic acid to patients with multiple myeloma to prevent skeletal problems. Researchers found that giving the drug every 12 weeks instead of every 4 weeks still kept the rate of such problems low, with only about 5.8% of patients experiencing these issues in the first year. This is important because it means patients can receive effective treatment with fewer doses, reducing the burden of frequent visits to the clinic. Who this helps: This helps patients with multiple myeloma by making their treatment regimen easier and less time-consuming.

Plain English
This study examined a drug called ONC201 to find out how it affects cancers related to blood, like mantle cell lymphoma and acute myeloid leukemia. Researchers discovered that ONC201 caused cancer cells to die without using the typical pathways related to a protein called p53, and it worked even in cases where cancer cells had become resistant to other treatments. Importantly, ONC201 could kill cancer stem cells while leaving normal cells unharmed, which suggests it might provide a safer treatment option for patients. Who this helps: This helps patients with hematological cancers, especially those resistant to standard therapies.

Plain English
The Asia-Pacific Hematology Consortium studied how doctors in the Asia-Pacific region diagnose and treat multiple myeloma, a type of blood cancer, by surveying participants at a conference in Beijing. The findings revealed gaps in knowledge and practices among physicians, highlighting the need for better communication and education. Improving these areas is crucial for providing better care for patients with this condition. Who this helps: This helps patients with multiple myeloma by ensuring they receive better diagnosis and treatment.

Plain English
This study looked at high-risk multiple myeloma, a type of blood cancer, focusing on specific genetic changes that can worsen a patient's outlook. It found that patients with genetic abnormalities like t(4;14) and del(17/17p) can improve their chances of survival with certain treatments, like bortezomib and carfilzomib, which can lead to better overall survival rates. However, more complex cases with multiple genetic issues do not benefit from these treatments, highlighting the need for careful testing and personalized treatment plans. Who this helps: This information benefits patients with multiple myeloma, their doctors, and researchers working on better treatments.

Plain English
This study focused on how to better evaluate treatment responses in patients with multiple myeloma, especially with the introduction of new, effective drugs. Researchers found that because many patients are achieving complete responses to treatment, it's important to establish new ways to measure deeper responses, including identifying leftover cancer cells in the bone marrow and using advanced imaging techniques. This is significant because it helps standardize how treatment success is reported and improves the understanding of patient outcomes. Who this helps: This benefits patients with multiple myeloma by ensuring they receive the most accurate assessments of their treatment responses.

Plain English
In this study, researchers investigated how natural killer (NK) cells derived from cord blood attack multiple myeloma (MM) cancer cells. They found that these NK cells kill MM cells not just directly, but also by transferring tiny particles (vesicles) that spread the killing effect to neighboring cells. This process increases the effectiveness of the NK cells, leading to more MM cell deaths, which is important because MM is currently incurable. Who this helps: This research benefits patients with multiple myeloma by providing insights for new treatments.

Plain English
This research looked at the risks of developing a serious blood condition called myelodysplastic syndrome (MDS) or acute leukemia after treatment for multiple myeloma, a type of cancer. Out of 55 patients studied, the average time between their multiple myeloma diagnosis and the development of MDS or leukemia was about 4.5 years, and once diagnosed with these conditions, patients lived an average of only 6.7 months. These findings highlight that while treatments for multiple myeloma have improved survival, they can lead to severe complications with poor outcomes. Who this helps: This information is important for patients with multiple myeloma and their doctors.

Plain English
This study looked at 24 patients with multiple myeloma who were on dialysis and received a specific type of stem cell transplant. The results showed that none of these patients died due to treatment complications within 100 days, and 92% responded positively to the treatment, with an average survival of about 3.8 years. However, only 3 patients were able to stop dialysis after the procedure, and higher doses of a treatment drug led to more side effects without providing clear benefits in survival. Who this helps: This research helps doctors in planning safer treatment options for multiple myeloma patients who are also on dialysis.

Plain English
Researchers gathered a group of experts to discuss how to best treat multiple myeloma patients whose cancer has returned after initial treatment. They found that for patients eligible for a second stem cell transplant, high-dose therapy should be standard if they didn’t have a transplant the first time, and it may also help those who had an initial transplant, especially if their first remission lasted more than 18 months. These findings are important because they provide clear guidelines for doctors on how to treat relapsed multiple myeloma, potentially leading to better outcomes for patients. Who this helps: This helps patients with multiple myeloma and their doctors.

Plain English
This study looked at 25 patients who developed unusual changes in their blood cells after receiving treatment for blood cancers but did not go on to develop any serious new conditions. The researchers found that these changes were often minor, typically involved only a small number of cells, and sometimes even disappeared over time. This is important because it shows that not all patients with these changes need to worry about developing new serious diseases, allowing for more tailored management of their care. Who this helps: This helps patients who have been treated for blood cancers and their doctors in understanding their health better.